Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Davis

Showing results (401-410 of 414) with videos related to

Pageof 42
Sort By:
Frontiers in Neuroscience|March 11, 2020
Segmentation and Classification in Digital Pathology for Glioma Research: Challenges and Deep Learning ApproachesTahsin Kurc, Spyridon Bakas, Xuhua Ren, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2013
Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidismPaul M Wehn, Paul E Harrington, Timothy J Carlson, et al.
JAMA|October 25, 2023
Sigh Ventilation in Patients With Trauma: The SiVent Randomized Clinical TrialRichard K Albert, Gregory J Jurkovich, John Connett, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 27, 2007
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockadeNarender R Gavva, Anthony W Bannon, David N Hovland, et al.
Environmental Microbiology|October 28, 2021
Prevalence, complete genome, and metabolic potentials of a phylogenetically novel cyanobacterial symbiont in the coral-killing sponge, Terpios hoshinotaYu-Hsiang Chen, Hsing-Ju Chen, Cheng-Yu Yang, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2010
The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine corePaul E Harrington, David J St Jean, Jeffrey Clarine, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in OncologyPeter G Shields, Roy S Herbst, Douglas Arenberg, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Pageof 42

Showing results (401-410 of 414) with videos related to

Sort By:
Pageof 42
Frontiers in Neuroscience|March 11, 2020
Segmentation and Classification in Digital Pathology for Glioma Research: Challenges and Deep Learning ApproachesTahsin Kurc, Spyridon Bakas, Xuhua Ren, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2013
Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidismPaul M Wehn, Paul E Harrington, Timothy J Carlson, et al.
JAMA|October 25, 2023
Sigh Ventilation in Patients With Trauma: The SiVent Randomized Clinical TrialRichard K Albert, Gregory J Jurkovich, John Connett, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 27, 2007
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockadeNarender R Gavva, Anthony W Bannon, David N Hovland, et al.
Environmental Microbiology|October 28, 2021
Prevalence, complete genome, and metabolic potentials of a phylogenetically novel cyanobacterial symbiont in the coral-killing sponge, Terpios hoshinotaYu-Hsiang Chen, Hsing-Ju Chen, Cheng-Yu Yang, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2010
The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine corePaul E Harrington, David J St Jean, Jeffrey Clarine, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in OncologyPeter G Shields, Roy S Herbst, Douglas Arenberg, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Pageof 42